Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch1 of Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials. Glenmark’s Lacosamide Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat®2 Injection, 200 mg/20 mL (10 mg/mL), of UCB, Inc. [NDA 022254]. According to IQVIA® sales data for the 12-month period ending April 2026, the Vimpat® Injection market3 achieved annual sales of approximately $15.2 million*. The company has attached media release in this regard.
The above information is a part of company’s filings submitted to BSE.
